Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, provides his impression of the Transcend-NHL study investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL).
